Skip to content

Mel Nelson

3 papers in the library · 30 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

Mu Opioid Receptor Activation is Required for NMDA Receptor Antagonist Effects on Stress-induced Maladaptive Behavior.

Biological Psychiatry July 7, 2025 Cory B Langreck, Briana K Chen, Victor M Luna et al. 9 citations

Contradictory evidence has emerged regarding the role of the mu opioid receptor (MOR) in the antidepressant actions of (R,S)-ketamine. Here, we used the long-acting MOR-selective antagonist methocinnamox (MCAM) to determine the contribution of MOR to the actions of (R,S)-ketamine and the more selective N-methyl-D-aspartate receptor (NMDAR) antagonist fluoroethylnormemantine (FENM) against...

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.

Nature Communications September 20, 2024 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 18 citations

Ibogaine and its main metabolite noribogaine provide important molecular prototypes for markedly different treatment of substance use disorders and co-morbid mental health illnesses. However, these compounds present a cardiac safety risk and a highly complex molecular mechanism. We introduce a class of iboga alkaloids - termed oxa-iboga - defined as benzofuran-containing iboga analogs and...

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

bioRxiv (Cold Spring Harbor Laboratory) July 23, 2021 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 3 citations preprint

Abstract Substance use and related mental health epidemics are causing increasing suffering and death in diverse communities. 1,2 Despite extensive efforts focused on developing pharmacotherapies for treating substance use disorders, there is an urgent need for radically different therapeutic approaches. 3,4 Ibogaine provides an important drug prototype in this direction, as a psychoactive...